Objective: to analyze the clinical efficacy of dupilumab in the treatment of moderate to severe atopic dermatitis. Methods: a total of 60 patients with moderate to severe atopic dermatitis treated in Beijing Jingcheng...Objective: to analyze the clinical efficacy of dupilumab in the treatment of moderate to severe atopic dermatitis. Methods: a total of 60 patients with moderate to severe atopic dermatitis treated in Beijing Jingcheng Skin Hospital (2021.1-2021.12) were divided into observation group (dupilumab) and control group (conventional treatment). The clinical efficacy (excellent + effective), the improvement time of clinical symptoms (eczema like skin lesions, dry skin, pruritus), EASI (total score of 6, the lower the better) and NRS (total score of 10, the lower the better) were compared after treatment. Results: there were significant differences in clinical efficacy between the observation group (dupilumab) and the control group (conventional treatment) after treatment (P 0.05). There was a significant difference in the improvement time of clinical symptoms between the observation group (dupilumab) and the control group (conventional treatment) after treatment (P 0.05). Before treatment, there were no differences in EASI and NRS scores between the observation group (dupilumab) and the control group (conventional treatment) (P > 0.05), but after treatment, there were differences in EASI and NRS scores between the observation group (dupilumab) and the control group (conventional treatment) (P 0.05). Conclusion: in the treatment of patients, the use of dupilumab can improve the treatment effect, the treatment is obvious, and the symptoms of patients are more obvious, the score of pruritus is more obvious, which is conducive to improve the quality of life of patients, and is worthy of being widely used in clinical practice.展开更多
文摘Objective: to analyze the clinical efficacy of dupilumab in the treatment of moderate to severe atopic dermatitis. Methods: a total of 60 patients with moderate to severe atopic dermatitis treated in Beijing Jingcheng Skin Hospital (2021.1-2021.12) were divided into observation group (dupilumab) and control group (conventional treatment). The clinical efficacy (excellent + effective), the improvement time of clinical symptoms (eczema like skin lesions, dry skin, pruritus), EASI (total score of 6, the lower the better) and NRS (total score of 10, the lower the better) were compared after treatment. Results: there were significant differences in clinical efficacy between the observation group (dupilumab) and the control group (conventional treatment) after treatment (P 0.05). There was a significant difference in the improvement time of clinical symptoms between the observation group (dupilumab) and the control group (conventional treatment) after treatment (P 0.05). Before treatment, there were no differences in EASI and NRS scores between the observation group (dupilumab) and the control group (conventional treatment) (P > 0.05), but after treatment, there were differences in EASI and NRS scores between the observation group (dupilumab) and the control group (conventional treatment) (P 0.05). Conclusion: in the treatment of patients, the use of dupilumab can improve the treatment effect, the treatment is obvious, and the symptoms of patients are more obvious, the score of pruritus is more obvious, which is conducive to improve the quality of life of patients, and is worthy of being widely used in clinical practice.
